Delcath Systems (NASDAQ:DCTH – Get Free Report) and Veracyte (NASDAQ:VCYT – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Delcath Systems and Veracyte, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 1 | 0 | 5 | 0 | 2.67 |
| Veracyte | 1 | 3 | 4 | 0 | 2.38 |
Delcath Systems currently has a consensus price target of $22.50, suggesting a potential upside of 107.56%. Veracyte has a consensus price target of $43.83, suggesting a potential upside of 27.68%. Given Delcath Systems’ stronger consensus rating and higher possible upside, equities analysts plainly believe Delcath Systems is more favorable than Veracyte.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Delcath Systems | $85.23 million | 4.38 | $2.70 million | $0.07 | 154.86 |
| Veracyte | $517.15 million | 5.30 | $66.35 million | $0.83 | 41.36 |
Veracyte has higher revenue and earnings than Delcath Systems. Veracyte is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Delcath Systems has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.
Insider & Institutional Ownership
61.1% of Delcath Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Comparatively, 1.4% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Delcath Systems and Veracyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | 3.17% | 2.63% | 2.39% |
| Veracyte | 12.83% | 8.05% | 7.38% |
Summary
Veracyte beats Delcath Systems on 8 of the 14 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
About Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
